1,298 material Form 8-K filings that 1,057 companies we cover made with the SEC in April 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Subsidiaries of CN Healthy Food Tech Group received an Advance Notice of Administrative Penalty from a China Securities Regulatory Commission bureau, which found the company did not complete mandatory offshore listing filings before its September 2025 Nasdaq listing via merger with Iron Horse Acquisition Company. The proposed fines would hit the subsidiary and the chief executive, and the filing does not state how the company's operations or finances are affected beyond these amounts.
CSRC Heilongjiang bureau intends to fine Zhongneng Liangke RMB3,000,000 (approximately $440,000)
Intended fine of RMB1,500,000 (approximately $220,000) on CEO and chairman Zhenjun Jiang as directly responsible executive
Notice dated April 24, 2026; subsidiaries have five working days to present a defense and request a hearing
Giftify received a Nasdaq notice on March 24, 2026, after its closing bid price stayed below $1 per share for 30 consecutive business days. In an April 27, 2026 letter, Nasdaq said the stock had closed at $1.00 or higher for 10 consecutive business days, from April 13 to April 24, 2026, and that the company had regained compliance with the minimum bid price rule. Nasdaq closed the matter, so the filing reports no delisting action.
Nasdaq notice dated March 24, 2026, cited Rule 5550(a)(2), which requires a $1 minimum bid price.
Closing bid price was below $1 for 30 consecutive business days before the notice.
Stock closed at $1.00 or higher for 10 consecutive business days, April 13 to April 24, 2026.
Nasdaq letter dated April 27, 2026 confirmed compliance and closed the matter.
BullFrog AI said Nasdaq notified it on April 21, 2026 that it had regained compliance with the $2.5 million minimum stockholders' equity requirement, after sales under its existing at-the-market and equity-line-of-credit facilities. The company will be under a mandatory one-year panel monitor starting April 21, 2026, and if Nasdaq finds it out of compliance during that period, it will not get additional time to regain compliance. The result keeps the Nasdaq listing in place for now, but the monitor and the equity sales used to meet the requirement are relevant to shareholders.
Nasdaq letter dated April 21, 2026 confirmed regained compliance with Listing Rule 5550(b)(1), which requires stockholders' equity of at least $2.5 million
Compliance was achieved through sales under the company's existing at-the-market sales facility and equity-line-of-credit facility
Mandatory panel monitor runs for one year from April 21, 2026; a new finding of non-compliance in that period gets no extra time to cure
CEO Vin Singh said the financing structures were minimally dilutive and extended the cash runway by over a year, into late 2027
Tilray Brands filed a Form 8-K to submit an opinion from DLA Piper LLP as an exhibit to its Registration Statement No. 333-290806. The filing is administrative and does not disclose financial results, a transaction, or a change in company operations.
Filed April 21, 2026, under Items 8.01 (Other Events) and 9.01 (Financial Statements and Exhibits).
Exhibit 5.1 is an opinion from DLA Piper LLP (US), with DLA Piper's consent included as Exhibit 23.1.
Exhibit 104 is the cover page Interactive Data File in Inline XBRL format.
The filing is signed by Mitchell Gendel, Global General Counsel.
Abbott disclosed that a federal court on April 10, 2026 preliminarily approved a proposed settlement of a consolidated shareholder derivative lawsuit against certain current and former directors and officers. The settlement centers on corporate governance commitments, and the defendants deny any wrongdoing; it takes effect only if the court grants final approval at a hearing on June 4, 2026.
Court preliminarily approved the proposed settlement on April 10, 2026, and set a final settlement hearing for June 4, 2026.
Abbott will maintain or adopt governance policies listed in Exhibit A to the settlement stipulation and will commit funds needed to implement them; no cash payment amount is stated.
Lead Plaintiffs' Counsel may request attorneys' fees and expenses of not more than $15.85 million, subject to court approval.
Shareholder objections and notices of intent to appear must be received by May 18, 2026.
Mustang Bio received a Nasdaq notice on April 15, 2026, saying its common stock closed below $1.00 per share for 30 consecutive business days, so it is not in compliance with the minimum bid price rule. The notice has no immediate effect on the stock's listing, but the company has until October 12, 2026 to regain compliance, and there is no assurance it will keep its Nasdaq listing.
Nasdaq notice received April 15, 2026; bid price closed below $1.00 for 30 consecutive business days
Compliance deadline is October 12, 2026, a 180-calendar day grace period
Compliance requires a closing bid price of at least $1.00 for a minimum of ten consecutive business days
Company may be eligible for a second 180-day period or may need a reverse stock split; no decision has been made
Alpha Cognition entered a settlement agreement dated April 10, 2026 with Galantos Pharma GmbH i.L., a company in liquidation, to extinguish future royalty and milestone payments under the Memogain Asset Purchase Agreement. In exchange for a one-time payment of EUR 5,214,220, Galantos agreed to release the company and its related parties from claims arising from the original agreement. The filing does not state the financial impact on the company's results.
One-time payment of EUR 5,214,220 to Galantos in full satisfaction of remaining contingent obligations, including royalty and milestone-related payments.
Galantos waives and releases the company and its related parties from causes of action arising from the Original Agreement.
Management states the settlement is an approximate 40% discount to the estimated market value of the remaining obligations, based on its own projections and comparable market benchmarks.
Agreement dated April 10, 2026; filed as Exhibit 10.1 to the report signed by CEO Michael McFadden on April 14, 2026.
Albertsons reported a fourth-quarter net loss of $480.8 million, or $0.94 per share, after a $599.8 million after-tax charge tied to a $774 million opioid settlement framework payable over nine years. Excluding the charge and other adjustments, fourth-quarter adjusted net income rose to $251.7 million, or $0.48 per share, from $0.46 a year earlier, and the board raised the quarterly dividend 13% and expanded the buyback authorization.
Q4 fiscal 2025 net loss of $(480.8) million, or $(0.94) per share, versus net income of $171.8 million, or $0.29 per share, a year earlier; adjusted net income was $251.7 million, or $0.48 per share.
Opioid Settlement Framework totals about $774 million over nine years; first payment expected April 30, 2026 into escrow; after-tax net present value of about $482 million; subject to participation by states, political subdivisions and trib
Quarterly dividend raised 13% to $0.17 per share from $0.15, payable May 8, 2026 to holders of record as of April 24, 2026; remaining share repurchase authorization increased by $900 million to $2.0 billion.
Fiscal 2026 outlook: adjusted EBITDA of $3.850 billion to $3.925 billion and adjusted net income per share of $2.22 to $2.32, compared with $2.18 in fiscal 2025.
Camden entered a binding term sheet on April 7, 2026 to settle the RealPage revenue-management software class action for $53 million, subject to a long-form agreement and Court approval. The company says the payments will not affect its 2026 Core FFO or Core AFFO and do not expect them to impair its credit rating or materially affect liquidity, leverage or dividend policy.
Aggregate settlement of $53 million, paid in two equal installments of $26.5 million
First installment due within 45 days of the long-form agreement; second within four months
Long-form agreement expected on or before May 7, 2026; preliminary approval motion expected by May 15, 2026
Settlement payments to be recorded as Other Non-Operating Expenses; company does not believe there is insurance coverage
CISO Global filed a no-action request with the SEC Staff on April 7, 2026, asking for confirmation that the Staff would not recommend enforcement under Rule 17Ad-20 if the company adopts a proposed Investor-Consent Share Loan Program. The filing contains no financial results or financial impact figures, and the company states there is no assurance the SEC Staff will grant relief or on what timing.
No-action request submitted April 7, 2026, and announced in a press release dated April 8, 2026.
Under the proposed program, shareholders would opt in before their shares are treated as available for securities lending, and could withdraw consent at any time.
Any SEC Staff response would reflect the Staff's views only and would not be a formal rule, regulation, or Commission approval.
Nick Morgan of the Investor Choice Advocates Network (ICAN) is assisting the company pro bono.
Jena Acquisition Corp II, a Cayman Islands blank check company, received a written notice on April 1, 2026 from NYSE Regulation stating it does not meet the requirement to maintain at least 300 public shareholders on a continuous basis. The company plans to submit a business plan to NYSE within 45 days showing how it will regain compliance within 18 months, and says the notice has no immediate effect on its listing or trading. For shareholders, the securities remain listed for now, but continued listing during the cure period depends on NYSE approving the plan.
Notice received April 1, 2026 from NYSE Regulation under the 300 public shareholder minimum.
Business plan due within 45 days of receipt; NYSE then has 45 days to review it.
Press release says the plan will involve completing a de-SPAC transaction; the 8-K cites Section 802.01A while the press release cites Section 802.01B.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.